1580053-60-6

Basic information

• Product Name: C₂₃H₃₀BrN₃O₂
• Synonyms: C₂₃H₃₀BrN₃O₂
• CAS NO: 1580053-60-6
• Molecular Weight: 460.414
• Mol File: 1580053-60-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₂₃H₃₀BrN₃O₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₃H₃₀BrN₃O₂(1580053-60-6)
• EPA Substance Registry System: C₂₃H₃₀BrN₃O₂(1580053-60-6)

Safety Data

• Hazardous Substances Data: 1580053-60-6(Hazardous Substances Data)

Upstream product

• 5349-24-6 N-butyl-2-chloroacetamide 
• 1554857-70-3 2-bromo-4-(bromomethyl)phenol 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 29922-56-3 2-bromo-4-(hydroxymethyl)phenol 
• 52703-21-6 2-bromo-4-(bromomethyl)phenol 

Downstream Products

• 1580053-36-6 4-butyl-7-((4-phenylpiperazin-1-yl)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one 

Relevant articles and documents

The synthesis of 4,7-disubstituted-2H-benzo[b][1,4]-oxazin-3(4H)-ones using Smiles rearrangement and their in vitro evaluation as platelet aggregation inhibitors

A series of novel benzo[b][1,4]oxazin-3(4H)-one derivatives were synthesized as platelet aggregation inhibitors for structure-activity relationships (SAR) analysis. The synthetic pattern, involved Smiles rearrangement for the preparation of benzoxazine, was proven to be more efficient than the conventional methods. Biological evaluation demonstrated that among all the synthesized compounds, compound 9u (IC50 = 9.20 μM) exhibited the most potent inhibition activity compared with aspirin, the positive control (IC50 = 7.07 μM). Molecular docking revealed that these set of compounds could be the GPIIb/IIIa antagonist for that they could be situated in the binding site of GPIIb/IIIa receptor quite well.